Lenvatinib/Pembrolizumab Yields Continuing Efficacy in Advanced Melanoma
Source: OncLive, June 2021
Lenvatinib (Lenvima) and pembrolizumab (Keytruda) continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment, according to updated findings of the LEAP-004 (NCT03776136) trial presented virtually during the 2021 ASCO Annual Meeting.1
